Tandem Diabetes Care Q4 2023 GAAP EPS $(0.46) Misses $(0.27) Estimate, Sales $196.80M Miss $202.76M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tandem Diabetes Care (TNDM) reported Q4 2023 GAAP EPS of $(0.46), missing the $(0.27) estimate, with sales of $196.80M also missing the $202.76M estimate. This represents a 10.75% decrease in sales compared to the same period last year.

February 21, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tandem Diabetes Care reported a significant miss in both EPS and sales for Q4 2023, with a notable year-over-year decrease in sales.
The significant miss in both EPS and sales expectations, coupled with a year-over-year decrease in sales, is likely to negatively impact investor sentiment and the stock price in the short term. The magnitude of the miss and the trend of decreasing sales are critical factors for investors, indicating potential underlying issues that could affect future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100